CERE - Cerevel Therapeutics Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
CERE price evolution
CERE
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $322.4 | $418.43 | $157.68 | $177.72 |
| Short term investments | $525.86 | $574.5 | $521.16 | $560.66 |
| Net receivables | $4.96 | $5.29 | $3.41 | $4.13 |
| Inventory | ||||
| Total current assets | $859.58 | $1006.94 | $687.79 | $751.67 |
| Long term investments | $218.59 | $185.2 | $81.34 | $88.64 |
| Property, plant & equipment | $44.6 | $45.77 | $47.19 | $48.26 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $267.77 | $236.36 | $134.18 | $142.68 |
| Total investments | $744.45 | $759.7 | $602.5 | $649.3 |
| Total assets | $1127.34 | $1243.3 | $821.96 | $894.35 |
| Current liabilities | ||||
| Accounts payable | $10.84 | $11.86 | $11.54 | $9.39 |
| Deferred revenue | ||||
| Short long term debt | $3.52 | $3.4 | $3.28 | $3.15 |
| Total current liabilities | $84.1 | $92.18 | $78.84 | $65.56 |
| Long term debt | $478.78 | $477.37 | $470.16 | $478.29 |
| Total noncurrent liabilities | $478.78 | $477.37 | $470.16 | $478.29 |
| Total debt | $482.3 | $480.78 | $473.44 | $481.44 |
| Total liabilities | $562.89 | $569.55 | $549 | $543.85 |
| Shareholders' equity | ||||
| Retained earnings | -$1532.51 | -$1400.6 | -$1267.94 | -$1171.58 |
| Other shareholder equity | -$1.09 | $1.77 | $1.68 | $1.14 |
| Total shareholder equity | $564.46 | $673.75 | $272.96 | $350.5 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $418.43 | $138.39 | $197.22 | $387.82 |
| Short term investments | $574.5 | $755.51 | $372.67 | |
| Net receivables | $5.29 | $2.05 | ||
| Inventory | ||||
| Total current assets | $1006.94 | $905.65 | $578.02 | $390.56 |
| Long term investments | $185.2 | $58.13 | $52.27 | |
| Property, plant & equipment | $45.77 | $49.29 | $51.7 | $48.62 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $236.36 | $112.17 | $110.9 | $54.71 |
| Total investments | $759.7 | $813.63 | $424.94 | |
| Total assets | $1243.3 | $1017.82 | $688.92 | $445.27 |
| Current liabilities | ||||
| Accounts payable | $11.86 | $10.06 | $11.3 | $4.99 |
| Deferred revenue | ||||
| Short long term debt | $3.4 | $2.9 | $2.44 | $2.04 |
| Total current liabilities | $92.18 | $72.56 | $42.54 | $29.55 |
| Long term debt | $477.37 | $335.48 | $67.65 | $30.97 |
| Total noncurrent liabilities | $477.37 | $424.02 | $67.65 | $31.2 |
| Total debt | $480.78 | $426.92 | $70.09 | $33.01 |
| Total liabilities | $569.55 | $496.58 | $110.19 | $60.75 |
| Shareholders' equity | ||||
| Retained earnings | -$1400.6 | -$967.75 | -$616.24 | -$390.91 |
| Other shareholder equity | $1.77 | $3.1 | -$0.99 | |
| Total shareholder equity | $673.75 | $521.24 | $578.73 | $384.52 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $106.42 | $97.13 | $85.25 | $74.08 |
| Selling, general & administrative | $36.23 | $42.44 | $26.05 | $22.76 |
| Total operating expenses | $142.66 | $139.56 | $111.31 | $96.84 |
| Operating income | -$142.66 | -$139.56 | -$111.31 | -$96.84 |
| Income from continuing operations | ||||
| EBIT | -$129.12 | -$129.82 | -$93.59 | -$96.79 |
| Income tax expense | $0.14 | $0.19 | $0.12 | $0.11 |
| Interest expense | $2.65 | $2.65 | $2.64 | $2.64 |
| Net income | ||||
| Net income | -$131.91 | -$132.66 | -$96.36 | -$99.53 |
| Income (for common shares) | -$131.91 | -$132.66 | -$96.36 | -$99.53 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $334.64 | $280.26 | $161.85 | $103.3 |
| Selling, general & administrative | $112.62 | $87.59 | $58.24 | $45.81 |
| Total operating expenses | $447.26 | $367.85 | $220.1 | $149.12 |
| Operating income | -$447.26 | -$367.85 | -$220.1 | -$149.12 |
| Income from continuing operations | ||||
| EBIT | -$421.77 | -$360.97 | -$225.33 | -$152.17 |
| Income tax expense | $0.5 | $0.16 | -$0.02 | |
| Interest expense | $10.57 | -$9.62 | ||
| Net income | ||||
| Net income | -$432.84 | -$351.51 | -$225.33 | -$152.14 |
| Income (for common shares) | -$432.84 | -$351.51 | -$225.33 | -$148.27 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | -$131.91 | -$132.66 | -$96.36 | -$99.53 |
| Operating activities | ||||
| Depreciation | $1.54 | $1.5 | $1.45 | $1.35 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $20.93 | $25.22 | $17.09 | $14.51 |
| Total cash flows from operations | -$119.67 | -$97.42 | -$72.63 | -$77.33 |
| Investing activities | ||||
| Capital expenditures | -$0.27 | -$0.9 | -$0.51 | -$2.06 |
| Investments | $19.44 | -$149.31 | $51.91 | $63.81 |
| Total cash flows from investing | $19.16 | -$150.21 | $51.39 | $61.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.47 | $508.37 | $1.2 | $6.36 |
| Net borrowings | $31.25 | |||
| Total cash flows from financing | $4.47 | $508.37 | $1.2 | $37.61 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$96.03 | $260.74 | -$20.04 | $22.04 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$432.84 | -$351.51 | -$225.33 | -$152.14 |
| Operating activities | ||||
| Depreciation | $5.63 | $4.9 | $2.73 | $0.4 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $69.41 | $38.78 | $23.94 | $10.26 |
| Total cash flows from operations | -$342.3 | -$293.19 | -$178.55 | -$117.8 |
| Investing activities | ||||
| Capital expenditures | -$3.81 | -$3.95 | -$10.5 | -$18.89 |
| Investments | $77.53 | -$384.88 | -$425.16 | |
| Total cash flows from investing | $73.72 | -$388.83 | -$435.66 | -$18.89 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $517.5 | $251.31 | $337.1 | $442.62 |
| Net borrowings | $31.25 | $372.27 | $31.25 | |
| Total cash flows from financing | $548.62 | $623.19 | $423.6 | $440.83 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $280.04 | -$58.83 | -$190.6 | $304.14 |
News
Fundamentals
| Market cap | $8.18B |
|---|---|
| Enterprise value | $8.34B |
| Shares outstanding | 181.89M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$443.48M |
| EBIT | -$449.33M |
| Net Income | -$460.47M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -17.76 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -18.80 |
| EV/EBIT | -18.56 |
| P/S ratio | N/A |
| P/B ratio | 14.46 |
| Book/Share | 3.11 |
| Cash/Share | 1.77 |
| EPS | -$2.53 |
|---|---|
| ROA | -45.07% |
| ROE | -98.94% |
| Debt/Equity | 0.85 |
|---|---|
| Net debt/EBITDA | -0.54 |
| Current ratio | 10.22 |
| Quick ratio | 10.22 |